Bioarctic Neuroscience AB is a research and product development company based in Stockholm, specializing in disease-modifying treatments for neurodegenerative diseases. The organization focuses on conditions such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). Bioarctic is committed to innovative research and development, aiming to advance therapeutic options in these challenging areas of medicine.
One of the notable projects undertaken by Bioarctic includes the development of a subcutaneous formulation of Leqembi®, a treatment for Alzheimer’s disease. The company collaborates with Eisai in the U.S. rolling supplemental Biologics License Application (sBLA) submission process, highlighting its active role in the regulatory landscape. Bioarctic also presents new data at conferences such as the CTAD, contributing to the scientific discourse surrounding neurodegenerative disorders.
In addition to its research initiatives, Bioarctic engages with capital markets and regularly publishes press releases and interim reports to inform stakeholders about its progress and developments. The company’s expertise in therapeutic areas related to neurodegenerative disorders positions it as a key player in the ongoing efforts to address these complex diseases.